Sagimet Biosciences Unveils Groundbreaking Preclinical Data in NASH Research
Sagimet Biosciences Inc. a clinical-stage biopharmaceutical entity, has recently made a significant announcement regarding its latest preclinical data at the 7th Obesity and NASH Drug Development Summit in Boston. The company’s Chief Medical Officer, Eduardo Bruno Martins, M.D., D.Phil., presented the study’s findings, which focused on the efficacy of the company’s fatty acid synthase (FASN) inhibitor, both as a standalone treatment and in conjunction with semaglutide, in a preclinical mouse model of nonalcoholic steatohepatitis (NASH).
The study leveraged an advanced artificial intelligence-based digital pathology platform to evaluate liver fibrosis, a critical indicator of the progression. The results demonstrated a notable decrease in liver fibrosis, primarily attributed to the inhibitor rather than semaglutide. Furthermore, transcriptomic profiling analysis revealed that the combination therapy of the FASN inhibitor with semaglutide produced additive effects and exhibited distinct mechanisms of action (MOAs). These findings suggest potential benefits for patients suffering from NASH and dysmetabolic syndrome.
Sagimet Biosciences is at the forefront of developing denifanstat, an oral, once-daily selective FASN inhibitor designed to address the unmet medical needs in NASH. The company’s lead drug candidate is currently in the midst of FASCINATE-2, a Phase 2b clinical trial that uses liver biopsy as the primary endpoint. Sagimet anticipates reporting topline results, including biopsy data, in the first quarter of the subsequent year.
The company’s strategic approach focuses on targeting dysfunctional metabolic pathways, specifically the overproduction of palmitate, a fatty acid linked to various diseases. Sagimet’s commitment to developing novel therapeutics is aimed at providing significant benefits to patients afflicted with conditions like NASH, for which there are no approved treatments in the United States or Europe.
Dr. Wen-Wei Tsai, Ph.D., presented the study titled “Evaluation of FASN inhibitor & GLP-1 Combination in Preclinical Mouse Model” at 12:30 p.m. ET on Tuesday, November 28, 2023. Sagimet Biosciences maintains a strong commitment to scientific communication and transparency, as evidenced by the availability of presentation details in the “Posters and Publications” section of its official communications.
Sagimet Biosciences’ research and development initiatives are integral to its broader mission of delivering innovative treatments to patients with serious health conditions. The company’s active role in metabolic disease research underscores its contribution to the advancement of knowledge and treatment options for complex health issues.
Sagimet Biosciences has shared promising preclinical data that supports the potential of its FASN inhibitor in treating NASH. The study’s findings contribute to the growing body of evidence that could lead to new therapeutic options for patients. The company’s focus on advancing denifanstat through clinical trials demonstrates its commitment to addressing the challenges faced by those living. As the scientific community continues to explore the complexities of metabolic diseases, the firm’s contributions are poised to make a meaningful impact on patient care.
Source link
